Abstract:Background: Aggressive thyroid carcinoma (ATC) usually loses radioiodine avidity to iodine-131 ( 131 I) due to the downregulation of sodium/iodide symporter (NIS). The expression of thyroid stimulating hormone receptor (TSHR) is more persistent than NIS and the administration of recombinant human thyroid stimulating hormone (rhTSH) promotes de novo NIS synthesis. Hence, exploring methods integrating 131 I with rhTSH might be a feasible therapeutic strategy for selective delivery of 131 I into thyroid cancer to fortify the effect of radioiodine ablation. Methods: The 131 I, poly (lactic-co-glycolic acid) (PLGA) and rhTSH were used to synthesize of the 131 I-PLGA-rhTSH nanoparticles. The characteristics of the 131 I-PLGA-rhTSH nanoparticles was determined using a light microscopy, scanning electron microscopy (SEM), autoradiography and immunofluorescence (IF) staining. The diameter of the 131 I-PLGA-rhTSH nanoparticles was measured with a Mastersizer 3000, and the encapsulation efficiency (EF) of 131 I in 131 I-PLGA-rhTSH nanoparticles and the radioactivity of a single nanoparticle were determined. Then, the mouse tumor xenograft model was established, and the biodistribution and effect of 131 I-PLGA-rhTSH nanoparticles on apoptosis of thyroid cance cells were investigated in vivo. Thereafter, the role of 131 I-PLGA-rhTSH nanoparticles in cell viability using cell counting kit-8 and lactate dehydrogenase (LDH) release assays. Subsequently, the underlying mechanism of 131 I-PLGA-rhTSH nanoparticles in reducing cell viability was assessed using immunostaining, boyden invasion assays and phalloidin staining. Results: Our results showed that the method of developing nanoparticles-encapsulated 131 I using poly (lactic-co-glycolic acid) (PLGA) and modified with rhTSH ( 131 I-PLGA-rhTSH), was a feasible avenue for the integration of 131 I and rhTSH. Meanwhile, the encapsulation efficiency (EF) of 131 I-PLGA-rhTSH nanoparticles was approximately 60%, and the radioactivity of a single nanoparticle was about 1.1×10-2 Bq. Meanwhile, the 131 I-PLGA-rhTSH nanoparticles were selectively delivered into, gradually enriched and slowly downregulated in xenograft tumor after the administration of 131 I-PLGA-rhTSH nanoparticles through tail vein in mouse tumor xenograft model. Thereafter, the tumor weight was significantly reduced after the administration of 131 I-PLGA-rhTSH nanoparticles. Subsequently, the application of 131 I-PLGA-rhTSH nanoparticles facilitated apoptosis and attenuated immobilization via inhibiting F-actin assembling of FTC-133 cells. Conclusion: The present study develops a suitable approach integrating 131 I and rhTSH, and this strategy is a feasible regimen enhancing the effect of radioiodine ablation for the treatment of thyroid cancer.

Nanoclay Drug-Delivery System Loading Potassium Iodide Promotes Endocytosis and Targeted Therapy in Anaplastic Thyroid Cancer

Emerging integrated nanoclay-facilitated drug delivery system for papillary thyroid cancer therapy

Current Application of Nanoparticle Drug Delivery Systems to the Treatment of Anaplastic Thyroid Carcinomas

Co-Delivery of 131I and Prima-1 by Self-Assembled CD44-Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics

A versatile nanoplatform carrying cascade Pt nanozymes remodeling tumor microenvironment for amplified sonodynamic/chemo therapy of thyroid cancer

Intercalated 2D nanoclay for emerging drug delivery in cancer therapy

Disrupting Glycolysis and DNA Repair in Anaplastic Thyroid Cancer with Nucleus-Targeting Platinum Nanoclusters.

Single Agent Nanoparticle for Radiotherapy and Radio-Photothermal Therapy in Anaplastic Thyroid Cancer.

Synthesis of lenvatinib-loaded upconversion@polydopamine nanocomposites for upconversion luminescence imaging-guided chemo-photothermal synergistic therapy of anaplastic thyroid cancer

Poly (lactic-co-glycolic acid)-encapsulated iodine-131 nanoparticles fabricated with rhTSH induce apoptosis and immobilization of thyroid cancer cells

Near-Infrared-Triggered Release of Ca2+ Ions for Potential Application in Combination Cancer Therapy.

Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer

BSA-Stabilized Mesoporous Organosilica Nanoparticles Reversed Chemotherapy Resistance of Anaplastic Thyroid Cancer by Increasing Drug Uptake and Reducing Cellular Efflux

Tailoring Morphologies of Mesoporous Polydopamine Nanoparticles to Deliver High-Loading Radioiodine for Anaplastic Thyroid Carcinoma Imaging and Therapy.

A Sequential Targeting Nanoplatform for Anaplastic Thyroid Carcinoma Theranostics.

An in Situ Spontaneously Forming Micelle-Hydrogel System with Programmable Release for the Sequential Therapy of Anaplastic Thyroid Cancer.

Low-intensity focused ultrasound-assisted dox-piperine amplified therapy on anaplastic thyroid carcinoma by hybird tumor-targeting nanoparticles

Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy

Host-Guest Polypyrrole Nanocomplex for Three-Stimuli-Responsive Drug Delivery and Imaging-Guided Chemo-Photothermal Synergetic Therapy of Refractory Thyroid Cancer

KCl Nanoparticles As Potential Inducer of Immunogenic Cell Death for Cancer Immunotherapy.

Antitumor Effect of 131 I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer